⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 4, 2024Open Access

Table S4 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study

Tero Sievänen Tiina Jokela Matti Hyvärinen Tia‐Marje Korhonen Kirsi Pylvänäinen Jukka‐Pekka Mecklin Juha Karvanen Elina Sillanpää Toni T. Seppälä Eija K. Laakkonen

View Full Paper

Ask AI

Bookmark

Share

Abstract

Table S4: C-miR full model. HR = hazard ratio, 95% CI = 95% confidence interval, b= regression coefficient, SE = standard error, df = degrees of freedom. P significant at 0.05 level.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sievänen et al. (2024) studied this question.

synapsesocial.com/papers/68e664bab6db6435875f13e1 https://doi.org/10.1158/1940-6207.25964394.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S4 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024
2Table S6 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024
3Table S6 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024
4Table S9 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024
5Table S9 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024